Literature DB >> 26441359

Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency.

Graziano Onder1, Alessandra Marengoni2, Pierluigi Russo3, Luca Degli Esposti4, Massimo Fini5, Alessandro Monaco3, Stefano Bonassi5, Katie Palmer3, Walter Marrocco3, Giuseppe Pozzi6, Diego Sangiorgi4, Stefano Buda4, Niccolò Marchionni7, Federica Mammarella8, Roberto Bernabei9, Luca Pani3, Sergio Pecorelli3.   

Abstract

BACKGROUND: In older adults co-occurrence of multiple diseases often leads to use of multiple medications (polypharmacy). The aim of the present study is to describe how prescription of medications varies across age groups, with specific focus on the oldest old.
METHODS: We performed a cross-sectional study using 2013 data from the OsMed Health-DB database (mean number of medicines and defined daily doses prescribed in 15,931,642 individuals). There were 3,378,725 individuals age 65 years or older (21.2% of the study sample).
RESULTS: The mean number of prescribed medications progressively rose from 1.9 in the age group <65 years to 7.4 in the age group 80-84 years and then declined, with a more marked reduction in the age group 95 years or older with a mean number of 2.8 medications. A similar pattern was observed for the mean number of defined daily doses. Among participants age ≥65 years, proton pump inhibitors were the most commonly prescribed medication (40.9% of individuals ≥65 years), followed by platelet aggregation inhibitors (32.8%) and hydroxy-methylglutaryl-coenzyme A reductase inhibitors (26.1%). A decline in prescription was observed among individuals age 90 years or older, but this reduction was less consistent for medications used to treat acute conditions (ie, antibiotics and glucocorticoids) rather than preventive medicines commonly used to treat chronic diseases (ie, antihypertensive medications and hydroxy-methylglutaryl-coenzyme A reductase inhibitors).
CONCLUSIONS: The burden of medication treatment progressively increases till age 85 and substantially declines after age of 90 years. Patterns of medication prescription widely vary across age groups.
Copyright © 2016 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Prescribing; end of life; polypharmacy

Mesh:

Year:  2016        PMID: 26441359     DOI: 10.1016/j.jamda.2015.08.009

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  12 in total

1.  Suspected adverse drug reactions (ADRs) trends in older Italian patients: an analysis from the National Pharmacovigilance Network.

Authors:  Gianluca Sferrazza; Giuseppe Nicotera; Pasquale Pierimarchi
Journal:  Aging Clin Exp Res       Date:  2019-08-19       Impact factor: 3.636

2.  The composition of polypharmacy: A register-based study of Swedes aged 75 years and older.

Authors:  Jonas W Wastesson; Angel Cedazo Minguez; Johan Fastbom; Silvia Maioli; Kristina Johnell
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

Review 3.  Allergy and Aging: An Old/New Emerging Health Issue.

Authors:  Massimo De Martinis; Maria Maddalena Sirufo; Lia Ginaldi
Journal:  Aging Dis       Date:  2017-04-01       Impact factor: 6.745

Review 4.  Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults - a systematic review.

Authors:  Maren Meinshausen; Anja Rieckert; Anna Renom-Guiteras; Moritz Kröger; Christina Sommerauer; Ilkka Kunnamo; Yolanda V Martinez; Aneez Esmail; Andreas Sönnichsen
Journal:  BMC Geriatr       Date:  2017-10-16       Impact factor: 3.921

5.  Medication use among older people in Europe: Implications for regulatory assessment and co-prescription of new medicines.

Authors:  Anna Strampelli; Francesca Cerreta; Katarina Vučić
Journal:  Br J Clin Pharmacol       Date:  2020-07-26       Impact factor: 4.335

6.  All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study.

Authors:  Luca Degli Esposti; Valentina Perrone; Chiara Veronesi; Stefano Buda; Roberta Rossini
Journal:  Vasc Health Risk Manag       Date:  2018-11-20

7.  Out of Pocket Payment and Affordability of Medication for Geriatric Patients in Tehran, Iran.

Authors:  Morvarid Zarif-Yeganeh; Mona Kargar; Arash Rashidian; Aarefeh Jafarzadeh Kohneloo; Kheirollah Gholami
Journal:  Iran J Public Health       Date:  2019-06       Impact factor: 1.429

8.  Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study.

Authors:  Laurie E Davies; Andrew Kingston; Adam Todd; Barbara Hanratty
Journal:  PLoS One       Date:  2021-01-19       Impact factor: 3.240

9.  Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars.

Authors:  Valentina Perrone; Stefania Saragoni; Stefano Buda; Alessandro Broccoli; Luca Degli Esposti
Journal:  Biologics       Date:  2016-12-01

10.  The epidemiology of polypharmacy in older adults: register-based prospective cohort study.

Authors:  Lucas Morin; Kristina Johnell; Marie-Laure Laroche; Johan Fastbom; Jonas W Wastesson
Journal:  Clin Epidemiol       Date:  2018-03-12       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.